Literature DB >> 27959740

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.

Marina Caskey1, Florian Klein1, Michel C Nussenzweig1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27959740     DOI: 10.1056/NEJMp1613362

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

1.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.

Authors:  Diogo M Magnani; Michael J Ricciardi; Varian K Bailey; Martin J Gutman; Núria Pedreño-Lopez; Cassia G T Silveira; Helen S Maxwell; Aline Domingues; Lucas Gonzalez-Nieto; Qin Su; Ruchi M Newman; Melissa Pack; Mauricio A Martins; José M Martinez-Navio; Sebastian P Fuchs; Eva G Rakasz; Todd M Allen; Stephen S Whitehead; Dennis R Burton; Guangping Gao; Ronald C Desrosiers; Esper G Kallas; David I Watkins
Journal:  Mol Ther       Date:  2017-07-24       Impact factor: 11.454

3.  Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV.

Authors:  Sarah B Lloyd; Keith P Niven; Ben R Kiefel; David C Montefiori; Arnold Reynaldi; Miles P Davenport; Stephen J Kent; Wendy R Winnall
Journal:  Hum Vaccin Immunother       Date:  2017-09-26       Impact factor: 3.452

Review 4.  Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.

Authors:  Jeffrey M Jacobson; Charles W Flexner
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 5.  Vaccine nanoparticles for protection against HIV infection.

Authors:  Marisa E Aikins; Joseph Bazzill; James J Moon
Journal:  Nanomedicine (Lond)       Date:  2017-02-21       Impact factor: 5.307

6.  Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.

Authors:  Shariq Mujib; Jun Liu; A K M Nur-Ur Rahman; Jordan A Schwartz; Phil Bonner; Feng Yun Yue; Mario A Ostrowski
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

7.  Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Authors:  Ling Xu; Amarendra Pegu; Ercole Rao; Nicole Doria-Rose; Jochen Beninga; Krisha McKee; Dana M Lord; Ronnie R Wei; Gejing Deng; Mark Louder; Stephen D Schmidt; Zachary Mankoff; Lan Wu; Mangaiarkarasi Asokan; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Jochen Kruip; Rebecca Sendak; Young Do Kwon; Tongqing Zhou; Xuejun Chen; Robert T Bailer; Keyun Wang; Misook Choe; Lawrence J Tartaglia; Dan H Barouch; Sijy O'Dell; John-Paul Todd; Dennis R Burton; Mario Roederer; Mark Connors; Richard A Koup; Peter D Kwong; Zhi-Yong Yang; John R Mascola; Gary J Nabel
Journal:  Science       Date:  2017-09-20       Impact factor: 47.728

8.  Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Authors:  Marina Tuyishime; Carolina Garrido; Shalini Jha; Matt Moeser; Dieter Mielke; Celia LaBranche; David Montefiori; Barton F Haynes; Sarah Joseph; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

9.  Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.

Authors:  Pablo K Valente; Yumeng Wu; Yehuda Z Cohen; Marina Caskey; Kathrine Meyers
Journal:  Clin Trials       Date:  2020-08-24       Impact factor: 2.486

10.  An Update on Antiretroviral Therapy.

Authors:  Luis Menéndez-Arias; Samara Martín-Alonso; Estrella Frutos-Beltrán
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.